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Background: Chronic hepatitis C infection is caused by the hepatitis C virus (HCV), and 
its clinical complications include liver cirrhosis, liver failure, and hepatocellular carci-
noma. Transforming growth factor-β1 (TGF-β1) is an important cytokine in cell growth 
and diﬀerentiation, angiogenesis, extracellular matrix formation, immune response 
regulation, and cancer development and progression.
Objectives: The aim of this study was to investigate the relationship between single nu-
cleotide polymorphisms (SNPs) in TGF-β1 and chronic HCV infection among patients re-
ferred to the Taleghani Hospital, Tehran, Iran between 2008 and 2010.
Patients and Methods: In this case-control study, samples were collected using a conveni-
ence sampling method. We genotyped 164 HCV patients and 169 healthy controls for 3 
SNPs in the TGF-β1 gene (-509 promoter, codon 10, and codon 25). We determined the 
SNP genotypes by using polymerase chain reaction-restriction fragment length poly-
morphism (PCR-RFLP) method. To conﬁrm the PCR-RFLP genotyping results, 10% of the 
samples were re-genotyped using a direct sequencing method.
Results: There were no signiﬁcant diﬀerences in the allelic frequency distribution of SNPs 
at -509 C/T, +869 C/T, or +915 G/C between HCV patients and the healthy controls. Geno-
typing results for all three polymorphic sites were similar with no statistically signiﬁ-
cant diﬀerences between the groups.
Conclusions: Most of the Iranian patients (over 85%), both healthy controls and HCV pa-
tients, had the GG genotype at the +915 G/C position, resulting in a high level of TGF-β1 
production. Therefore, we concluded that the SNPs investigated by us cannot be consid-
ered as prognostic factors for HCV infection in our population, despite being reported 
as prognostic markers in other populations. Moreover, there is a possibility that most of 
the population is susceptible to HCV infection.
  c 2011, BRCGL, Published by Kowsar M.P.Co.  All rights reserved.
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 Implication for health policy/practice/research/medical education:
Transforming growth factor beta-1 (TGF-β1) is a multifunctional cytokine that acts as a regulator of proliferation and cellular dif-
ferentiation. Investigation of the association of single nucleotide polymorphisms (SNPs) in TGF-β1 gene sequence with increased 
or decreased individual’s susceptibility to chronic diseases such as hepatitis C infection could be helpful to ﬁnd appropriate and 
population speciﬁc genetic biomarkers.
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1. Background
Approximately 175 million people worldwide are in-
fected with hepatitis C virus (HCV), and about 80% of 
these individuals develop chronic HCV infection. Some 
individuals with persistent HCV infections develop liver 
cirrhosis, which can lead to hepatocellular carcinoma in 902 TGF-β1 Polymorphisms and Chronic Hepatitis C in Iran Romani S et al.
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some patients (1-4). Hepatitis C has a complex etiology; 
factors such as genetic predisposition and cytokine pro-
duction levels contribute to the pathogenesis (5). Cyto-
kines play a vital role in the body’s ability to ﬁght viral 
infections: they determine the main type of immune re-
sponse triggered and directly inhibit viral proliferation 
(6). Host genetic variations such as single nucleotide 
polymorphisms (SNPs) in cytokine genes can aﬀect the 
rate of HCV production or secretion (7). Transforming 
growth factor-β (TGF-β) is an important cytokine for cell 
growth and diﬀerentiation, angiogenesis, extracellular 
matrix formation, immune response regulation, and 
cancer development and progression (8-10). Changes 
in the secretion of immune suppressive factors such as 
TGF-β can cause dysregulation of host immune response 
in chronic HCV patients (5, 11).
The TGF-β superfamily consists of 3 main isoforms, 
namely, TGf-β1, TGf-β2, and TGf-β3. TGF-β1 is a dimeric pro-
tein that acts either as a hormone or locally as a regulator 
of proliferation, diﬀerentiation, extracellular matrix pro-
duction, and cell death (12). Characteristics of the extra-
cellular matrix may also contribute to the clinical symp-
toms of liver diseases such as HCV infection (13). Several 
studies have reported diﬀerences in cytokine production 
among patients; this diﬀerence could be attributable to 
variation in the levels of gene expression or in secretion 
levels of cytokines.
2. Objectives
In this study, we investigated three important SNPs 
in the TGF-β1 gene. Two SNPs are found in the signal se-
quence of the early producing protein and one in the 
promoter region. These polymorphisms can aﬀect the 
gene expression or secretion levels of the mature protein 
(14, 15). One SNP in codon 25 of TGF-β1’s signal sequence 
was previously associated with an individual’s suscepti-
bility to chronic HCV infection (3). The aim of the present 
study was to determine whether any of the three selected 
TGF-β1 polymorphisms are associated with chronic HCV 
infection in an Iranian population.
3. Patients and Methods
3.1. Study Population
We conducted a case-control study by using samples 
collected using a convenience sampling method from 
individuals at the Taleghani Hospital of Tehran between 
March 2008 and October 2010. The study population con-
sisted of 333 Iranian individuals, including 164 patients 
with HCV infection and 169 healthy controls. In the pa-
tient group, HCV infection was diagnosed using a third-
generation enzyme-linked immunosorbent assay with 
anti-HCV antibodies (DRG International Inc., USA). We ex-
cluded patients co-infected with hepatitis B virus (HBV) 
or human immunodeﬁciency virus (HIV); these patients 
were identiﬁed using tests for hepatitis B surface anti-
gen and/or anti-HIV antibodies (DRG International Inc., 
USA). To conﬁrm HCV infection in patients who yielded 
positive results in the anti-HCV antibody test, circulat-
ing viral RNA was identiﬁed using reverse transcription-
polymerase chain reaction (RT-PCR). The healthy control 
group consisted of volunteer blood donors who had 
no history of hepatitis or hepatobiliary disorders and 
showed negative results for anti-HCV antibodies and 
HCV-RNA.
3.2. RNA Extraction and RT-PCR
Viral RNA was extracted from 200 μL of plasma with 
the QIAmp viral RNA mini kit (Qiagen, Hilden, Germany), 
according to the manufacturer’s instructions. Comple-
mentary DNA was synthesized in a total volume of 32.5 
μL, consisting of 1 μL of random hexamer primers, 5 μL 
of ssRNA template (100 ng), 4 μL of 5× buﬀer, 0.5 μL of Ri-
bolock RNase inhibitor, 2 μL of dNTP mix, 200 U of Rever-
tAidTM M-MuLV reverse transcriptase, and 19 μL of RNase-
free water (Fermentas, Latvia). Reverse transcription was 
carried out at 42°C for 1 h.
3.3. TGF-β Gene Polymorphisms
Peripheral blood samples from all 333 subjects were 
collected and stored at 4°C. Genomic DNA was extracted 
from whole blood by using a standard phenol–chloro-
form method. Genotyping of the 3 SNPs in the TGF-β 
gene, namely, the -509 C/T SNP in the promoter, the +869 
T/C SNP in codon 10, and the +915 G/C SNP in codon 25, 
was performed using PCR-restriction fragment length 
polymorphism (RFLP). The PCR conditions for the SNPs 
in codons 10 and 25 were as follows: 95°C for 5 min; 35 
cycles of 95°C for 30 s, 58.4°C for 30 s, and 72°C for 30 s; 
and a ﬁnal extension at 72°C for 10 min. The PCR condi-
tions for the -509 SNP were as follows: 95°C for 5 min; 30 
cycles of 95°C for 30 s, 62°C for 45 s, and 72°C for 30 s; and 
a ﬁnal extension at 72°C for 10 min. For genotyping the 
SNP at -509, we used previously described primers (16). 
The target sequence was ampliﬁed by PCR to yield a 153-
bp product. Subsequently, the PCR product was digested 
using the Eco81I restriction enzyme (Fermentas, Latvia). 
For genotyping the SNPs of codons 10 and 25, we de-
signed a pair of primers that ampliﬁed both polymor-
phic sites. This PCR product was used as a template for 
two RFLP reactions with MspA1I (Promega, USA) for co-
don 10 and BglI (Fermentas, Latvia) for codon 25. The 
primer sequences, digestion conditions, and restriction 
enzymes for the detection of each SNP are given in Table 
1. Ampliﬁcation of 100 ng of template DNA for each of the 
2 PCR reactions was performed using a total volume of 25 
μL containing 10 pmol of forward and reverse primers, 
1.25 U of Taq polymerase, 200 μM of each dNTP (Fermen-
tas, Latvia), 37 mM of MgCl2, 1.25 μL of dimethylsulphox-
ide (Sigma Aldrich, Germany), and distilled deionized 
water. The PCR products were run on a 1.5% agarose gel 
and stained with ethidium bromide for visualization 
under UV light. The RFLP products for codon 25 and -509 
promoter SNPs were visualized on a 2% agarose gel; the 
RFLP products for codon 10 were separated and visual-903 TGF-β1 Polymorphisms and Chronic Hepatitis C in Iran Romani S et al.
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ized using 16% polyacrylamide gel electrophoresis.
3.4. DNA Sequencing
To conﬁrm the RFLP genotyping results, we re-geno-
typed over 10% of the samples (45 samples) by using di-
rect sequencing with an ABI genetic analyzer 3130xl and 
a chain-termination protocol.
3.5. Statistical Analysis
The consistency of the genotyping results was exam-
ined with Hardy–Weinberg equilibrium. Logistic regres-
sion and chi-square tests were used to compare the geno-
type frequencies between the HCV and control groups. 
Age diﬀerences between the 2 groups were compared as 
a quantitative variable by using an independent sample 
t test. SPSS version 13 software and the logistic regression 
test were used to evaluate the odds ratio (conﬁdence in-
terval = 95%).
4. Results
In this study, we recruited a total of 164 HCV patients 
(132 men and 32 women) with a mean age of 47.9 ± 13.8 
years. The control group consisted of 169 individuals (85 
men and 84 women) with a mean age of 41.07 ± 17.5 years. 
The percentage of men in the HCV group was higher than 
that in the control group, and the mean age was higher 
in the HCV group than in the control group. The TGF-β1 
polymorphisms in the -509, +869 (CTG to CCG), and +915 
(CGG to CCG) sites were genotyped in all the subjects. Fig-
ure 1 shows the RFLP products for codon 25 on a 2% aga-
rose gel. The allelic frequencies of the three SNPs in the 
chronic HCV patients and the healthy subjects are given 
in Table 2. The chi-square test was used to analyze the re-
lationship between the genotypes and hepatitis status. 
There was no signiﬁcant diﬀerence in the allelic distri-
bution of the three polymorphic sites between the HCV 
group and the control group (P > 0.05).
Table 3 presents a summary of the TGF-β1 genotypes for 
the three polymorphic sites in the promoter, codon 10, 
and codon 25 among the HCV patients and the healthy 
Figure 1. Representative Photograph of RFLP Electrophoresis on 2% Aga-
rose Gel for TGF-β1 Codon 25 Restricted Fragments With BglI Enzyme
A) GG genotype 212bp and 252bp, B) GC genotype 212bp, 252bp and 312bp, 
C) CC genotype 212bp and 312bp, D) DNA size marker 100bp.
Figure 2. DNA Sequence of TGF-β1 Gene. 
Codon 10 and Codon 25 polymorphisms. The sequence was read in re-
verse direction and N shows the site of polymorphism.
Primer Sequence PCR Annealing 
Temperature,°C
Restriction 
Enzyme
RFLP Incubation
 Temperature,°C
Codon 10 (+869) F: 5- GTTATTTCCGTGGGATACTGAGAC-3 58.4 MspA1I 30
Codon 25 (+915) R: 5- GACCTCCTTGGCGTAGTAGTCG -3 58.4 BglI 37
Promoter (-509) F: 5- CAGTAAATGTATGGGGTCGCAG -3 
R: 5- GGTGTCAGTGGGAGGAGGG -3
60.2 Eco81I 37
Table 1. Primer Sequence and Restriction Enzymes for Three Polymorphism Sites of TGF-β1 Gene
Allele Chronic HCV Patients, No. (%) Healthy Blood Controls, No. (%) P value a
TGF-β codon 10 0.424
T
C
183 (54.1)
155 (45.9)
181 (55.2)
147 (44.8)
TGF-β codon 25 0.526
G
C
308 (93.9)
20 (6.1)
318 (94.1)
20 (5.9)
TGF-β -509 0.368
T
C
178 (54.3)
150 (45.7)
178 (52.7)
160 (47.3)
Table 2. Allelic Frequencies of TGF-β Gene Among Patients With Chronic HCV Infection and Healthy Blood Donors
a P values are calculated using chi-square test and conﬁrmed by logistic regression.904 TGF-β1 Polymorphisms and Chronic Hepatitis C in Iran Romani S et al.
Hepat Mon. 2011;11(11):901-906
controls. According to results of the chi-square test, 
there were no statistically signiﬁcant diﬀerences in gen-
otype variants of the studied polymorphic sites between 
the HCV and control groups (P > 0.05). The mean age of 
the HCV patients was greater than that of the healthy 
controls, and the percentage of men was higher in the 
HCV group than in the healthy control group; therefore, 
we used the logistic regression method to remove these 
confounding variables. The results of RFLP genotyping 
for the three polymorphic sites were conﬁrmed using 
the direct sequencing method (Table 4); this showed that 
the results of the two methods were consistent. Figure 
2 shows a sample of the polymorphic sequences for co-
dons 10 and 25.
5. Discussion
A number of genes contribute to the diﬀerence in the 
cytokine levels observed in individuals; however, the 
mechanism of function of these genes has not been fully 
understood (7, 17, 18). Because cytokines regulate the im-
mune response, polymorphisms in cytokine genes or 
variations in their expression may aﬀect an individual’s 
susceptibility to infectious diseases (19, 20). TGF-β1 has a 
regulatory role in proliferation, diﬀerentiation, and acti-
vation of immune cells. Therefore, diﬀerences in its pro-
duction or secretion in the individuals in a population 
might result in diﬀerent responses to a given infectious 
agent (21, 22). An appropriate immune response to HCV 
infection is essential for its clearance from the blood and 
bodily ﬂuids. Therefore, defective or insuﬃcient produc-
tion or secretion of cytokines could aﬀect an individual’s 
ability for virus clearance and prevention of chronic dis-
ease. As such, genetic variations, such as SNPs, in a popu-
lation may aﬀect an individual’s susceptibility to chronic 
infectious diseases.
The most commonly studied polymorphisms of TGF-β1 
include a T/C transition at the -509 position of the pro-
moter region, a T/C transition in codon 10, and a G/C 
transversion in codon 25. The genotypic distribution 
of TGF-β1 polymorphisms varies in diﬀerent popula-
tions (23). Several studies have investigated the relation-
ship between polymorphisms in the TGF-β1 promoter 
or signal sequence and various diseases in the Iranian 
population. To our knowledge, however, there is limited 
information on the relationship between these polymor-
phisms and HCV infection in the Iranian population. 
Eurich et al. (2011) observed that the genotypes of TGF-β1 
polymorphisms in codons 10 and 25 are signiﬁcantly dif-
ferent in HCV patients with diﬀerent degrees of hepatic 
ﬁbrosis (24).
Pereira  et al. (2008) investigated the association of 
polymorphisms in TGF-β and three other cytokines with 
HCV infection in a Brazilian population. There was a sta-
tistically signiﬁcant relationship between the polymor-
TGF-β1 Polymorphism Restriction Enzyme Genotype Restricted Fragments, bp
Codon 10 (+869) MspA1I
CC
CT
TT
12, 40, 67, 108, 230
12, 40, 67, 108, 230, 242
40, 67, 108, 242
Codon 25 (+915) BglI
GG
GC
CC
212, 252, 60
212, 252, 312
212, 312
Promoter (-509) Eco81I
TT
CT
CC
153
153,117,36
117,36
Table 4. Restriction Fragments for Three RFLP Reactions
Polymorphism Genotype Chronic HCV Patients, No.(%) 
(n = 164)
Healthy Blood Controls, No.(%)
(n = 169)
P value
TGF-β codon 10 0.956
T/T
C/T
C/C
49 (29)
85 (50.3)
35 (20.7)
50 (30.5)
81 (49.4)
33 (20.1)
TGF-β codon 25 0.780
G/G
G/C
C/C
145 (88.4)
18 (11)
1 (0.6)
151 (89.3)
16 (9.5)
2 (1.2)
TGF-β -509 (Promoter) 0.920
Table 3. Genotypic Frequencies of TGF-β Gene Among Patients With Chronic HCV Infection and Healthy Blood Donors905 TGF-β1 Polymorphisms and Chronic Hepatitis C in Iran Romani S et al.
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phism in codon 25 of TGF-β1 and HCV infection; however, 
there was no such association with the polymorphisms 
in codon 10 (3). In contrast, Migita et al. observed that the 
site in codon 25 is not polymorphic among a Japanese 
population sample (25); this ﬁnding was conﬁrmed by 
Suzuki et al. (23). A study in China by Xie et al. showed 
that all the 186 HBV patients in their study had the GG ho-
mozygous genotype in codon 25; they also found no sig-
niﬁcant diﬀerence in codon 10 or promoter region (-509) 
polymorphisms between the case and control groups 
(17). These studies suggest that the site in codon 25 is 
not polymorphic among East Asian populations; this 
could be attributable to an ethnic diﬀerence between 
East Asians and other populations, such as Brazilians and 
Iranians. However, our results regarding codon 25 diﬀer 
from those of previous studies. The polymorphism in co-
don 25 was detected in both the HCV and control groups; 
however, there was no signiﬁcant diﬀerence in the fre-
quency of the genotypes between the two groups. For the 
polymorphism in codon 10, our ﬁndings were consistent 
with those of a previous study conducted on a Brazilian 
population (3); in both studies, there was no statisti-
cally signiﬁcant diﬀerence in the genotype between the 
chronic HCV patients and healthy controls.
Awad et al. (14) and Dunning et al. (15) observed that in-
dividuals with the G allele in TGF-β1 codon 25 exhibited 
a high cytokine-production phenotype. In our study, 
most of the Iranian patients in both the HCV and control 
groups exhibited high TGF-β1 production. Furthermore, 
according to Pereira et al. high TGF-β1 production is as-
sociated with increased HCV susceptibility; therefore, we 
hypothesize that patients with the GG genotype in codon 
25 are more susceptible to HCV than other populations. 
Because of the predominance of a high-production phe-
notype among the studied Iranian population and the 
eﬀect of high TGF-β levels on increased susceptibility to 
viral infections similar to HCV, we assume that most of 
the patients in our population are more susceptible than 
those in other populations, such as Brazilians. However, 
the results of our study indicate that TGF-β1 polymor-
phisms cannot be used as prognostic factors for chronic 
HCV infection in the Iranian population.
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